Search clinical trials for: Desvenlafaxine Succinate Sustained-Release Formulation 50 mg

Total 132 results

Pfizer

Completed

Study Comparing Discontinuation Symptoms Of DVS SR In Subjects With Major Depressive Disorder (MDD)

Major Depressive Disorder
Pfizer

Completed

Relapse Prevention Study Of Desvenlafaxine Succinate Sustained Release In Outpatients With Major Depressive Disorder

Major Depressive Disorder

Canada, United States, Colombia, Croatia, Estonia, Finland, Poland, France, Slovakia, Chile, Latvia, Lithuania, Romania, South Africa
Pfizer

Completed

Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) in Adult Outpatients With Major Depressive Disorder (MDD)

Major Depressive Disorder

United States
Wyeth is now a wholly owned subsidiary of Pfizer
Pfizer

Completed

Study Evaluating Desvenlafaxine Succinate Sustained Release In Adults With Major Depressive Disorder

Major Depressive Disorder

United States
Jiangsu Province Nanjing Brain Hospital

Not yet recruiting

Efficacy and Safety of Toludesvenlafaxine Hydrochloride Sustained-release Tablets Versus Desvenlafaxine Succinate Sustained-release Tablets Targeting Anhedonia in Patients With Major Depression Disorder

Anhedonia
Pfizer

Completed

A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD

Major Depressive Disorder

United States, Chile, Mexico
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating Safety, Tolerability, and PK of DVS SR in Healthy Japanese Women

Vasomotor Symptoms
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study of the Safety and Efficacy of Desvenlafaxine Succinate for Vasomotor Symptoms in Postmenopausal Women

Menopause | Vasomotor System

United States
LG Chem

Unknown

Food-effect Bioavailability of Fixed Dose Combination Zemimet® SR Tab. 50/1000 mg Under Fed and Fasting Conditions

Type2 Diabetes
Pfizer

Completed

Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) In The Treatment Of Peri- And Postmenopausal Women With Major Depressive Disorder (DVS 3364)

Major Depressive Disorder

United States
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating Desvenlafaxine Succinate Sustained Release In Outpatients With Major Depressive Disorder

Depressive Disorder, Major
Wyeth is now a wholly owned subsidiary of Pfizer

Terminated

Study Evaluating the Long-Term Safety of Desvenlafaxine Succinate Sustained-Release (DVS SR) in Subjects With Pain Associated With Diabetic Peripheral Neuropathy

Diabetic Neuropathy, Painful
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating Desvenlafaxine Succinate Sustained-Release Tablets (DVS SR) In The Treatment Of Child and Adolescent Outpatients With Major Depressive Disorder

Depressive Disorder, Major Depressive Disorder

United States
Pfizer

Completed

Study Evaluating Long-Term Safety of Desvenlafaxine Succinate Sustained Release With Japanese Adult Subjects in Major Depressive Disorder (MDD)

Major Depressive Disorder

Japan
Pfizer

Completed

Phase 1 Study To Test the Bioequivalence Between Two 25 mg Tablets vs. One 50 mg Tablet Under Fast/Fed Condition and Evaluate Food Effect of Desvenlafaxine Succinate Sustained Release (DVS SR)

Depression - Major Depressive Disorder

Belgium
Pfizer

Completed

The Effect Of Dose Titration And Dose Tapering On The Tolerability Of DVS SR In Women With Vasomotor Symptoms

Vasomotor Symptoms

Canada, United States
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) In The Treatment Of Child And Adolescent Outpatients With Major Depressive Disorder

Depression | Major Depressive Disorder

United States
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Unknown

A Study of Sustained-Release Desvenlafaxine Hydrochloride for the Treatment of Major Depressive Disorder

Major Depressive Disorder

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Completed

Study of Desvenlafaxine in Treating Major Depressive Disorder.

Major Depressive Disorder

China
Pfizer

Completed

Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) in the Treatment of Major Depressive Disorder

Major Depressive Disorder

United States, Japan
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating the Efficacy and Safety of Desvenlafaxine Tablets in Adult Outpatients With Major Depressive Disorder

Depressive Disorder, Major

Finland, France, South Africa, Estonia, Croatia, Lithuania, Latvia, Slovakia, Poland, Romania
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating the Pharmacokinetics of Venlafaxine Extended-Release (ER) and Desvenlafaxine Succinate Sustained-Release (DVS SR) 50 mg in Healthy Subjects

Healthy

United States
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) Versus Placebo in Peri- and Postmenopausal Women

Depressive Disorder | Depression | Depressive Disorder, Major

United States
Mochida Pharmaceutical Company, Ltd.
Pfizer

Completed

A Study of MD-120 in Patients With Depression

Major Depressive Disorder

Japan
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating DVS SR in Patients With Fibromyalgia Syndrome

Fibromyalgia

United States
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating DVS-233 for Treatment of Outpatients With Major Depressive Disorder

Major Depressive Disorder
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evalutating the Pharmacokinetics (PK) and Safety of a Single Dose of Desvenlafaxine Sustained Release (DVS SR)

Depressive Disorder, Major

United States
Pfizer

Completed

Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) In The Treatment Of Major Depressive Disorder

Depressive Disorder, Major

United States
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) vs. Escitalopram in Postmenopausal Women

Depressive Disorder | Depression | Depressive Disorder, Major

Colombia, Mexico, United States, Peru, Chile, Argentina
AstraZeneca

Completed

AZD9056 Relative Bioavailability Study

Healthy

United Kingdom
Cerevel Therapeutics, LLC

Completed

Pharmacokinetics of CVL-231 Following Single Oral Administration of Modified- and Immediate-release Formulations in Fasted and Fed Healthy Participants

Schizophrenia

United States
Pfizer's Upjohn has merged with Mylan to form Viatris...

Completed

Bioavailability of 3 Sildenafil Oral Disintegrating Tablet Formulations Compared to the Standard Oral Tablet

Healthy Volunteers

United States
Pfizer

Completed

A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD

Major Depressive Disorder

United States, Mexico
Pfizer

Completed

Study Evaluating the Effect of Desvenlafaxine on the Pharmacokinetics of Midazolam

Major Depressive Disorder

United States
Lyndra Inc.

Terminated

Study Determining Gastric-Retentive and Modified Release Properties of Prototype Capsules in Healthy Subjects

Healthy | Gastric Retention

United Kingdom
Pfizer

Completed

Open-Label Drug Interaction Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) 100mg On The Pharmacokinetics Of Tamoxifen When Coadministered To Healthy Post-Menopausal Female Subjects

Pharmacokinetics

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

Pharmacokinetic and Safety Trial to Determine the Appropriate Dose for Pediatric Patients With Multidrug Resistant Tuberculosis

Pediatric | Multidrug Resistant Tuberculosis

Philippines, South Africa
University Health Network, Toronto
Canadian Society of Hospital Pharmacists

Withdrawn

Dosing Intervals of Opioid Medication for Chronic Pain

Chronic Pain

Canada
Genuine Research Center, Egypt
Hikma Pharma

Completed

Bioequivalence Study of Solifenacin Succinate & Mirabegron From Mirfenacin MR 5/50 mg Extended Release Tablets (Hikma Pharma, Egypt) Versus Vesicare 5 mg FCT & Betmiga 50 mg Prolonged-Release Tablets (Astellas Pharma Europe B.V, the Netherlands / Astellas Pharma Europe B.V, the Netherlands)

Healthy

Egypt
Max Zeller Soehne AG

Completed

Pilot Pharmacokinetic Study of a Prolonged-release Formulation of St. John's Wort Extract Ze 117

Healthy

Germany
Abbott

Recruiting

Trial of Itopride 150mg Once a Day Versus Itopride 50 mg Thrice a Day; in Patients With Functional Dyspepsia

Functional Dyspepsia

Malaysia, Armenia
XenoPort, Inc.

Completed

A Safety and Efficacy Study of XP19986 in Subjects With Spasticity Due to Spinal Cord Injury

Muscle Spasticity

United States
ViiV Healthcare
GlaxoSmithKline

Completed

Relative Bio-availability Study of Dolutegravir and Lamivudine Fixed Dose Combinations

Infection, Human Immunodeficiency Virus

United States
Janssen Research & Development, LLC

Completed

A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants

Healthy

United States
Pfizer

Completed

Open Label Drug Interaction Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) 100mg On The Pharmacokinetics Of Aripiprazole When Coadministered To Healthy Subjects

Pharmacokinetics | Cytochrome P-450 CYP2D6 | CYP3A4 Protein, Human

United States
LG Life Sciences

Completed

Food-Effect Bioavailability Study of FDC(Gemigliptin/Metformin HCl Sustained Release) 50/1000mg(25/500mg x 2tablets)

Type 2 Diabetes

Korea, Republic of
LG Chem

Completed

BE Study of the Combinations of Gemigliptin/Metformin HCl Extended Release 50/1000mg(25/500mg x 2 Tablets) in Comparison to Each Component Administered Alone

Healthy Male Volunteers

Korea, Republic of
Janssen Research & Development, LLC

Completed

A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components

Healthy Volunteers

United States
LG Chem

Completed

Bioequivalence Study for Fixed Dose Combination Zemimet® SR Tab. 50/1000 and Coadministration of Gemigliptin 50 mg and Metformin 1000 mg.

Type 2 Diabetes

Thailand
LG Chem

Unknown

Bioequivalence Study for Gemigliptin/Metformin 50/1000 mg and Coadministration of Gemigliptin 50 mg and Metformin 1000 mg.

Type2 Diabetes

3

Subscribe